International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
International Journal of Stroke shared a post on X about a recent article, by Sohei Yoshimura, published in SAGE Publishing, adding:
”Study finds oral anticoagulant alone and DOAC with antiplatelet therapy were associated with higher risks of major bleeding events than single antiplatelet therapy.”
Title: Long-term risk of bleeding events in patients taking antithrombotic agents for cerebrovascular or cardiovascular disease
Authors: Sohei Yoshimura, Kaori Miwa, Masatoshi Koga, Kanta Tanaka, Yoshiki Yagita, Yoshinari Nagakane, Haruhiko Hoshino, Tadashi Terasaki, Masayuki Shiozawa, Yasuyuki Iguchi, Shuji Arakawa, Shigeru Fujimoto, Yasushi Okada, Masafumi Ihara, Shinichi Takahashi, Ryosuke Doijiri, Makoto Sasaki, Yusuke Yakushiji, Teruyuki Hirano, Kazunori Toyoda
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis